{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:44:16Z","timestamp":1761396256132,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>(1) Background: The WHO identified COVID-19 as a fast-growing epidemic worldwide. A few antivirals have shown promising effectiveness in treating COVID-19. This study aimed to assess the correlation between antiviral drugs and the time until viral clearance of SARS-CoV-2. (2) Methods: This was a retrospective cohort study that included 1731 non-severe COVID-19 patients treated in NMC Royal Hospital, UAE. (3) Results: A total of 1446 patients received symptomatic treatment only (mean age of 35.6 \u00b1 9.0 years). The analyzed antiviral treatment protocols were azithromycin, hydroxychloroquine, lopinavir\/ritonavir, and favipiravir. The produced Kaplan\u2013Meier plots showed no significant differences in the time until viral clearance among the compared protocols, which showed overlapping confidence intervals, which were determined by performing the log-rank and adjusted pairwise log-rank tests (p = 0.2, log-rank = 9.3). The age and gender of patients did not significantly affect the rate of viral clearance regardless of the antiviral therapy administered, even when compared to patients who received symptomatic treatment only, with the exception of hydroxychloroquine (HCQ), azithromycin, and favipiravir, which increased the odds of a faster rate of viral clearance by 46% after adjustments. (4) Conclusions: No significant differences were observed regarding the time until viral clearance among non-severe COVID-19 patients following the prescription of different antiviral drugs.<\/jats:p>","DOI":"10.3390\/antibiotics11040498","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T12:11:14Z","timestamp":1649419874000},"page":"498","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1203-0808","authenticated-orcid":false,"given":"Wael","family":"Hafez","sequence":"first","affiliation":[{"name":"NMC Royal Hospital, 16th Street, Khalifa City, Abu Dhabi P.O. BOX 35233, United Arab Emirates"},{"name":"The Medical Research Division, Department of Internal Medicine, The National Research Center, El Buhouth Street, Cairo 12622, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husam","family":"Saleh","sequence":"additional","affiliation":[{"name":"NMC Royal Hospital, 16th Street, Khalifa City, Abu Dhabi P.O. BOX 35233, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4220-3266","authenticated-orcid":false,"given":"Ziad","family":"Al Baha","sequence":"additional","affiliation":[{"name":"NMC Royal Hospital, 16th Street, Khalifa City, Abu Dhabi P.O. BOX 35233, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mishal","family":"Tariq","sequence":"additional","affiliation":[{"name":"NMC Royal Hospital, 16th Street, Khalifa City, Abu Dhabi P.O. BOX 35233, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samah","family":"Hamdan","sequence":"additional","affiliation":[{"name":"NMC Royal Hospital, 16th Street, Khalifa City, Abu Dhabi P.O. BOX 35233, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shougyat","family":"Ahmed","sequence":"additional","affiliation":[{"name":"NMC Royal Hospital, 16th Street, Khalifa City, Abu Dhabi P.O. BOX 35233, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug Treatment Options for the 2019-New Coronavirus (2019-NCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Biosci. Trends"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture","volume":"58","author":"Jochmans","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with Lopinavir\/Ritonavir or Interferon-\u03921b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of Lopinavir\/Ritonavir in the Treatment of SARS: Initial Virological and Clinical Findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative Therapeutic Efficacy of Remdesivir and Combination Lopinavir, Ritonavir, and Interferon Beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_6","first-page":"1192","article-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","volume":"6","author":"Cai","year":"2020","journal-title":"Eng. Beijing China"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol Monotherapy Is Superior to Lopinavir\/Ritonavir in Treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New Insights on the Antiviral Effects of Chloroquine against Coronavirus: What to Expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of Action of Hydroxychloroquine and Chloroquine: Implications for Rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/14787210.2020.1813024","article-title":"Azithromycin in the Treatment of COVID-19: A Review","volume":"19","author":"Horcajada","year":"2021","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(20)31862-6","article-title":"Azithromycin in Addition to Standard of Care versus Standard of Care Alone in the Treatment of Patients Admitted to the Hospital with Severe COVID-19 in Brazil (COALITION II): A Randomised Clinical Trial","volume":"396","author":"Furtado","year":"2020","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.medj.2020.04.001","article-title":"Efficacy and Safety of Lopinavir\/Ritonavir or Arbidol in Adult Patients with Mild\/Moderate COVID-19: An Exploratory Randomized Controlled Trial","volume":"1","author":"Li","year":"2020","journal-title":"Med"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Alhumaid, S., Al Mutair, A., Al Alawi, Z., Alhmeed, N., Zaidi, A.R.Z., and Tobaiqy, M. (2020). Efficacy and Safety of Lopinavir\/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis. Trop. Med. Infect. Dis., 5.","DOI":"10.3390\/tropicalmed5040180"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17460441.2019.1581171","article-title":"Broad-Spectrum Coronavirus Antiviral Drug Discovery","volume":"14","author":"Totura","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_16","first-page":"477","article-title":"Viral Shedding and Antibody Response in 37 Patients with Middle East Respiratory Syndrome Coronavirus Infection","volume":"62","author":"Corman","year":"2016","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"110538","DOI":"10.1016\/j.mehy.2021.110538","article-title":"Persistent SARS-2 Infections Contribute to Long COVID-19","volume":"149","author":"Jacobs","year":"2021","journal-title":"Med. Hypotheses"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_19","first-page":"5788","article-title":"Viral Kinetics and Factors Associated with Rapid Viral Clearance during Lopinavir\/Ritonavir-Based Combination Therapy in Non-Severe COVID-19 Patients","volume":"24","author":"Ding","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10928-014-9363-3","article-title":"Viral Kinetic Modeling: State of the Art","volume":"41","author":"Canini","year":"2014","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.3346\/jkms.2020.35.e86","article-title":"Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea","volume":"35","author":"Kim","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.2223","article-title":"Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies","volume":"110","author":"Gastine","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., and Lu, M. (2020). Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. MedRxiv.","DOI":"10.1101\/2020.03.17.20037432"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/jcpt.13305","article-title":"Observational Study of the Effects of Favipiravir vs Lopinavir\/Ritonavir on Clinical Outcomes in Critically Ill Patients with COVID-19","volume":"46","author":"Tomak","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"107702","DOI":"10.1016\/j.intimp.2021.107702","article-title":"Favipiravir in the Treatment of Patients with SARS-CoV-2 RNA Recurrent Positive after Discharge: A Multicenter, Open-Label, Randomized Trial","volume":"97","author":"Zhao","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jiph.2020.12.017","article-title":"Comparing ICU Admission Rates of Mild\/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir","volume":"14","author":"Guner","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2020.05.002","article-title":"Safety and Efficacy of Early High-Dose IV Anakinra in Severe COVID-19 Lung Disease","volume":"146","author":"Pontali","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"621676","DOI":"10.3389\/fphar.2021.621676","article-title":"No Efficacy of the Combination of Lopinavir\/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison","volume":"12","author":"Gagliardini","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., and Zhang, Z. (2020). Efficacy of Hydroxychloroquine in Patients with COVID-19: Results of a Randomized Clinical Trial. MedRxiv.","DOI":"10.1101\/2020.03.22.20040758"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and Microbiological Effect of a Combination of Hydroxychloroquine and Azithromycin in 80 COVID-19 Patients with at Least a Six-Day Follow up: A Pilot Observational Study","volume":"34","author":"Gautret","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101738","DOI":"10.1016\/j.tmaid.2020.101738","article-title":"Early Treatment of COVID-19 Patients with Hydroxychloroquine and Azithromycin: A Retrospective Analysis of 1061 Cases in Marseille, France","volume":"35","author":"Million","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"bjgpopen20X101094","DOI":"10.3399\/bjgpopen20X101094","article-title":"Should Azithromycin Be Used to Treat COVID-19? A Rapid Review","volume":"4","author":"Gbinigie","year":"2020","journal-title":"BJGP Open"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/bies.201200099","article-title":"Sex Influences Immune Responses to Viruses, and Efficacy of Prophylaxis and Treatments for Viral Diseases","volume":"34","author":"Klein","year":"2012","journal-title":"BioEssays News Rev. Mol. Cell. Dev. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Salciccia, S., Eisenberg, M.L., Maggi, M., Lai, S., Mastroianni, C.M., Pasculli, P., Ciardi, M.R., Canale, V., Ferro, M., and Busetto, G.M. (2021). Modeling the Contribution of Male Testosterone Levels to the Duration of Positive COVID Testing among Hospitalized Male COVID-19 Patients. Diagnostics, 11.","DOI":"10.3390\/diagnostics11040581"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"665","DOI":"10.21037\/atm-21-445","article-title":"Clinical Features in Coronavirus Disease 2019 (COVID-19) Patients with Early Clearance and Prolonged Shedding of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA","volume":"9","author":"Zhou","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1111\/bcp.14314","article-title":"Dosing Will Be a Key Success Factor in Repurposing Antivirals for COVID-19","volume":"87","author":"Smith","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2000799","DOI":"10.1183\/13993003.00799-2020","article-title":"Factors Associated with Prolonged Viral Shedding and Impact of Lopinavir\/Ritonavir Treatment in Hospitalised Non-Critically Ill Patients with SARS-CoV-2 Infection","volume":"56","author":"Yan","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"648660","DOI":"10.3389\/fmed.2021.648660","article-title":"SARS-CoV-2 Viral Shedding and Transmission Dynamics: Implications of WHO COVID-19 Discharge Guidelines","volume":"8","author":"Badu","year":"2021","journal-title":"Front. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e202101049","DOI":"10.26508\/lsa.202101049","article-title":"Incomplete Antiviral Treatment May Induce Longer Durations of Viral Shedding during SARS-CoV-2 Infection","volume":"4","author":"Kim","year":"2021","journal-title":"Life Sci. Alliance"},{"key":"ref_42","unstructured":"(2022, March 01). National Guidelines for Clinical Management and Treatment of COVID-19, Available online: https:\/\/www.dha.gov.ae\/en\/HealthRegulation\/Documents\/COVID%20National%20Guidelines%20F-NAL%2018%20March.pdf."},{"key":"ref_43","unstructured":"(2022, March 01). Clinical Managment of COVID-19\u2014Intterim Guidance. Available online: https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwiD8On8jID3AhVDXRoKHcrIBOgQFnoECAsQAQ&url=https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F332196%2FWHO-2019-nCoV-clinical-2020.5-eng.pdf&usg=AOvVaw3KMolfl2CddTXJJH9o7N4J."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/4\/498\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:50:27Z","timestamp":1760136627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/4\/498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["antibiotics11040498"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11040498","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2022,4,8]]}}}